DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK…
Marginal Zone Lymphoma – Epidemiology – Epidemiology – Marginal Zone Lymphoma – Mature Markets
Clarivate Epidemiology’s coverage of marginal zone lymphoma (MZL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Unmet Need – Unmet Need – Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Leukemia (US/EU)
Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a type of B-cell non-Hodgkin’s lymphoma and represents the most common form of leukemia in adults. The R/R CLL treatment…
